Pharmacokinetic of Everolimus and Atorvastatin Co-administration

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis : In renal transplantation recipient who received immunosuppressive drug "certican" and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase inhibitors. Because atorvastatin and everolimus have metabolism via Cytochrome P450 subfamily 3A4 both, so investigator made the hypothesis that when patients received everolimus with atorvastatin will change area under the time concentration curve of everolimus.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chulalongkorn University
• Collaborator: Ratchadapiseksompotch Research Fund
• Treatments: Atorvastatin; Atorvastatin Calcium; Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Post renal transplantation recipient who received immunosuppressive drug Everolimus and has hypercholesterolemia

• Co everolimus level within 3-12 ng/mL

• Informed consent

• Patient can follow research methodology

Exclusion Criteria:

• Patient don't want to participate in the study

• Post renal transplantation recipient who have normal lipid profile